HR 2931
108th Congress
House
Orphan Drug Tax Credit Act of 2003
Official title: To provide for the expansion of human clinical trials qualifying for the orphan drug credit.
Taxation
Clinical trialsCommerceDrug industryHealth
More subjectsShow fewer subjects
Income taxOrphan drugsPharmaceutical researchResearch and development tax creditScience, Technology, Communications
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 25, 2003
Referred to the House Committee on Ways and Means.
Jul 25, 2003
Introduced in House
Ask about this bill
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Latest action
Referred to the House Committee on Ways and Means.
Plain-English summary
Orphan Drug Tax Credit Act of 2003 - Amends the Internal Revenue Code to move up the date for which a taxpayer may claim the credit for the clinical testing of drugs for rare diseases or conditions (orphan drugs) from the date a drug is designated an orphan drug to the date the application for such designation is filed.
Bill text
1 version
- Introduced in House Formatted Text PDF
Committees of jurisdiction
1
Cite this page
U.S. Congress. (2026). H.R. 2931: Orphan Drug Tax Credit Act of 2003. 108th Congress. Open America. https://openamerica.io/bill/108-HR-2931/
"H.R. 2931: Orphan Drug Tax Credit Act of 2003." 108th Congress, 2026, Open America, https://openamerica.io/bill/108-HR-2931/.
H.R. 2931, 108th Cong. (2026), https://openamerica.io/bill/108-HR-2931/.
[H.R. 2931: Orphan Drug Tax Credit Act of 2003](https://openamerica.io/bill/108-HR-2931/)